⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14716385 | 0.98 | — | — | |
| SCHEMBL31566557 | 0.86 | — | — | |
| SCHEMBL5500902 | 0.82 | — | — | |
| SCHEMBL101460 | 0.82 | — | — | |
| SCHEMBL24152314 | 0.77 | — | — | |
| SCHEMBL4126698 | 0.77 | — | — | |
| SCHEMBL101752 | 0.77 | — | — | |
| SCHEMBL18703614 | 0.76 | — | — | |
| SCHEMBL6195423 | 0.76 | — | — | |
| SCHEMBL6222795 | 0.75 | ALDH1A1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025051241-A1 | MACROCYCLIC COMPOUND AND ANTIBODY-DRUG CONJUGATE THEREOF | 劲方医药科技(上海)股份有限公司 | 2025-03-13 | — | — | WO | disclosed |
| WO-2024022244-A1 | HETEROCYCLIC COMPOUND HAVING BIOLOGICAL ACTIVITY | 首药控股(北京)股份有限公司 | 2024-02-01 | — | — | WO | disclosed |
| US-20230293517-A1 | ANTAGONIST COMPOUNDS | JANSSEN PHARMCEUTICA NV (BE) | 2023-09-21 | — | — | US | disclosed |
| US-20230293517-A1 | ANTAGONIST COMPOUNDS | JANSSEN PHARMCEUTICA NV (BE) | 2023-09-21 | — | — | US | disclosed |
| US-20220411367-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC | 2022-12-29 | — | — | US | disclosed |
| US-20220411367-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC | 2022-12-29 | — | — | US | disclosed |
| EP-4041228-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E. Shaw Research, LLC (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114727993-A | Arylmethylene heterocyclic compounds as Kv1.3 potassium SHAKER channel blockers | D·E·萧尔研究有限责任公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2022023772-A1 | ANTAGONIST COMPOUNDS | AdoRx Therapeutics Limited (GB) | 2022-02-03 | — | — | WO | disclosed |
| WO-2021071812-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021071812-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
| CN-106458992-B | Pyridyl piperidine | 默克专利股份公司 | 2019-03-15 | — | — | CN | disclosed |
| EP-3297989-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016191312-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-12-01 | — | — | WO | disclosed |
| US-8822688-B2 | Imidazo[1,2-a]pyridine derivative | ASTELLAS PHARMA INC. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-8822688-B2 | Imidazo[1,2-a]pyridine derivative | ASTELLAS PHARMA INC. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-20130053363-A1 | IMIDAZO[1,2-a]PYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130053363-A1 | IMIDAZO[1,2-a]PYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2013-02-28 | — | — | US | disclosed |
| CN-102858772-A | Imidazo[1,2-a]pyridine derivative | ASTELLAS PHARMA INC | 2013-01-02 | — | — | CN | disclosed |